As part of my ongoing journey in computational biology and drug discovery, I recently worked on evaluating the pharmacokinetic and drug-likeness properties of selected compounds.
Using SwissADME, I performed detailed analysis of physicochemical properties, lipophilicity, solubility, and assessed compliance with Lipinski’s Rule of Five to determine drug-likeness.
Further, I extended the study to ADMET profiling (Absorption, Distribution, Metabolism, Excretion, and Toxicity) to better understand the biological behavior, safety, and efficacy of these compounds within the human body.
🧪 Key Highlights:
🔹 Drug-likeness screening and pharmacokinetics prediction
🔹 GI absorption and BBB permeability analysis
🔹 Evaluation of metabolic interactions and toxicity risks
🔹 Integration of in silico tools for efficient drug candidate selection
This experience strengthened my understanding of early-stage drug discovery and the importance of combining multiple computational approaches for better prediction accuracy.
Comments
Post a Comment